Tesamorelin visceral fat

Abdominal fat on CT

Tesamorelin turns a vague wish to “lose belly fat” into a precise clinical question. Its U.S. approval dates to 2010 and covers excess abdominal fat in adults with HIV-associated lipodystrophy. Lipodystrophy is abnormal fat redistribution; the pivotal work involved adults with HIV receiving antiretroviral therapy.

The principal tissue of interest was visceral adipose tissue, deep inside the abdomen around the organs. It was quantified as an area on CT. I trust that specificity more than a generic promise of weight loss because it identifies exactly where the proposed benefit lives.

Tesamorelin is a synthetic analog of the full 44-amino-acid GHRH signal, protected from rapid enzymatic breakdown by a modification at one end. It stimulates the pituitary to release the body's growth hormone. General fat-loss, anti-ageing, cognitive and non-HIV fatty-liver applications remain off-label and investigational.

Trunk fat; lean tissue

The 2026 meta-analysis pooled five randomised controlled trials in HIV-associated lipodystrophy. Visceral fat had a mean difference of -27.71 square centimetres, with a 95% confidence interval of -38.37 to -17.06. Trunk fat decreased by 1.18 kilograms, hepatic fat fraction by 4.28 percentage points, and lean body mass increased by 1.42 kilograms. All these results had p<0.001.

I favour those tissue measurements; a solitary scale reading feels crude. Fat and lean tissue moved in opposite directions. The lean-mass result came from people being treated for HIV-associated fat redistribution; it supplies no measurement of strength or muscle gain in healthy trained adults.

In the six-month JAMA trial of 50 antiretroviral-treated adults with HIV, the visceral-fat treatment effect was -42 square centimetres, p=0.005, and the hepatic lipid-to-water percentage fell by a net 2.9 percentage points, p=0.003. The liver finding is another reason to care about tissue location.

Discontinuation

In the 52-week programme in adults with HIV-associated abdominal fat accumulation, visceral-fat reduction was sustained at 18% over 52 weeks, p<0.001 against baseline. Visceral fat reaccumulated when treatment was discontinued.

That return deserves room in any account of the benefit. The reduction merits respect; I also regard its dependence on continued treatment as a central limitation. A temporary change in a fat depot asks a different practical question from a lasting change after treatment ends.

CJC-1295 shares tesamorelin's receptor target, but its healthy-adult hormone studies cannot inherit this outcome. Nor can ipamorelin's ferret result. Each experiment has its own direction of travel.

Metabolic observations

A two-week study in 13 healthy men measured insulin sensitivity alongside hormone changes. Mean overnight growth hormone increased by 0.5 micrograms per litre, p=0.004, and IGF-1 by 181 micrograms per litre, p<0.0001. Neither fasting glucose, p=0.93, nor insulin-stimulated glucose uptake, p=0.61, was significantly affected. Glucose changes in the 52-week patient programme were not clinically significant.

Those findings are reassuring within the studied populations and periods. Modest glucose disturbance can still occur. The rise in IGF-1 also leaves a longer oncological question: no excess malignancy signal appeared over 52 weeks, while long-term cancer-safety data remain limited and active malignancy is a labelled contraindication.

The NIH LiverTox monograph assigns a likelihood score of E, meaning an unlikely cause of clinically apparent liver injury, and records no attributable cases. The five-trial pooled analysis reported no serious adverse events; that observation does not settle safety across every population or longer exposure.

Of these three compounds, tesamorelin has the clinical record I trust most within its stated limits. Its authority belongs to the approved product and the indication studied. Research-grade tesamorelin lacks that product's pharmaceutical quality oversight, and all three peptides remain prohibited in sport under WADA category S2, in and out of competition.